Vita Life Sciences Limited · ASX:VLS
Vita Life Sciences — H1 2016 Earnings Presentation
17 slides from Vita Life Sciences's earnings presentation, Aug 22, 2016
Slide 1: Results Presentation Half Year ended 30 June 2016
Vita Life Sciences Ltd ASX: VSC Results Presentation Half Year ended 30 June 2016 herbsoigald vitasciende Vital ife Dedicated fo your health Enriching Lives . Since 1947 Vi 22 August 2016
Slide 2: Asia Pacific pharmaceutical and healthcare over-the-counter business
¾ Asia Pacific pharmaceutical and healthcare over-the-counter business involved in the formulating, formulating packaging, packaging sales and distribution of vitamins and supplements ¾ 750 - 800 registered sku of vitamins and supplements sold in 7 countries in the Asia Pacific region ¾ 3 major bran
Slide 3: Revenue EBIT DPS - interim
Revenue EBIT DPS - interim (A$m) (A$m) (cps) 20 3 2 15 2 10 1 1 5 0 0 0 2015 2016 2015 2016 2015 2016 2
Slide 4: Established markets: Australia, Singapore and Malaysia had mixed results
Established markets: Australia, Singapore and Malaysia had mixed results ¾ Australia: Achieved record revenue and EBIT margin growth ¾ Singapore: Stable revenues, decline in EBIT margins associated with the establishment t bli h t off the th Herbs H b off Gold G ld b brand d ¾ Malaysia: Stable reven
Slide 5: Other Asia performance adversely impacted by:
Other Asia performance adversely impacted by: ¾ Vietnam continued to grow steadily and Thailand has recovered ¾ Malaysia MLM revenue contracted to $0.2m in HY16 mainly due to the turnover of key distributors ¾ No N revenue ffrom Indonesia I d i in i HY16 with i h sales l anticipated i i d to commenc
Slide 6: Australia: Sales revenue of $8.1m, increased 12% against HY15
Revenue ($m) 10 8 ¾ Sales revenue of $8 $8.1m, 1m increased 12% against HY15; 6 Herbs of Gold 4 o Revenue base was sustained in a 2 competitive Australian market 0 2015 2016 o Sales via international distribution agreement made a positive EBIT ($m) 3 contribution Rollout R ll t off th the Vit Vi
Slide 7: Singapore: Sales revenue of $3.1m, in line with HY15
Revenue ($m) 4 ¾ Sales revenue of $3.1m, was in line with HY15 VitaHealth sales increased 2 Herbs of Gold sales decreased ¾ EBIT of $0.8m decreased 15.5% against 0 HY15 2015 2016 EBIT ($m) Margins impacted by lower Herbs of Gold 1 sales during the brand’s establishment phase 0.5 0 2015 2016 No
Slide 8: Malaysia: Sales revenue of $5.6m, declined 2% against HY15
Revenue ($m) 8 ¾ Sales revenue of $5 $5.6m, 6m declined 2% against HY15 Revenue base was sustained in 4 continued i d diffi difficultl economic i and d trading di conditions ¾ EBIT of $0.7m increased 10% against HY15 0 2015 2016 Despite difficult trading conditions the EBIT ($m) continued focus
Slide 9: Interim dividend declared of 1.5 cents per share for HY16
¾ Interim dividend declared of 1.5 cents per share for HY16 (1.5 cent HY15) ¾ Interim dividend will be unfranked & contains 100% Conduit Foreign Income ¾ Dividend reinvestment plan is currently suspended ¾ The decrease in gross operating cashflow conversion to EBITDA is due to working capital it l t
Slide 10: Managing Director long service leave
¾ The Company’s Managing Director, Mr. Eddie Tie, has served the Group continuously for almost 12 years. Mr. Tie will take long service leave from October to December 2016. 2016 During his absence, absence Mr.Mr Andrew O’Keefe, O’Keefe who is presently CEO of the Company’s Australian operations, wil
Slide 11: Trading update
Trading update Based on trading g to June 2016 and no material changes g within the Company’s p y regions g of operation Directors provide the following guidance for the 2016 full year; guidance of ∼$39m; ¾ Full yyear revenue g ¾ Full year EBIT guidance of $6.00m to $6.75m. 10
Slide 12: 11
11
Slide 13: Half year ended 30 June
Half year ended 30 June 2016 2015 $m $m Revenue 18.1 18.2 EBITDA 3.1 2.4 EBIT 30 3.0 24 2.4 Profit before tax 2.9 2.3 Profit after tax 1.8 1.6 EPS (Diluted – cents) 33 3.3 28 2.8 Dividend (cents / share) 1.50 1.50 12
Slide 14: Balance Sheet as at 30 June
Balance Sheet as at 30 June 31 December 2016 2015 $m $m Current assets 22 3 22.3 23 5 23.5 Non-current assets 10.8 8.9 Total assets 33.1 32.4 Current liabilities 7.0 6.9 Non-current liabilities 2.6 2.6 Total Liabilities 9.6 9.5 Net Assets 23.5 22.9 13
Slide 15: Cash Flow for the half year ended
Cash Flow for the half year ended 2016 2015 $m $m Receipts p from customers 19.6 20.1 Payments to suppliers and employees (18.6) (16.7) Gross operating cash flow 1.0 3.4 EBITDA 3.1 2.4 Gross operating cash flow / EBITDA 32% 142% Net interest ((paid)) / received ((0.0)) ((0.0)) Income tax paid (0.1)
Slide 16: Contact Details
Contact Details Telephone: p +61 3 9828 0500 Website: www.vitalifesciences.com.au Email: enquiries@vitalifesciences.com.au Head Office: Suite 650, 1 Queens Road, Melbourne, VIC 3004 15
Slide 17: Disclaimer
This document has been prepared by Vita Life Sciences Limited (Vita Life) and comprises written material/slides for a presentation concerning Vita Life. The presentation is for information purposes only and does not constitute or form part of any offer or invitation to acquire, sell or otherwise dis